Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNP520 prevention study in cognitively unimpaired adults at risk for Alzheimer's disease
NL-OMON50603Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing CNP520 with Placebo (2 arms). Primary endpoints: Time to diagnosis of MCI due to Alzheimer's disease or dementia due to Alzheimer's disease and API Preclinical Cognitive Composite score. Started Jul 2018; status: active, not recruiting.
02
Drugs
umibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON50603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50603.